Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sun And Taro Strike Generic Price-Fixing Settlement

US Subsidiaries Will Pay $85m To Settle With Direct Purchaser Plaintiffs

Executive Summary

Sun Pharma’s US subsidiaries have agreed to pay out $85m to settle US antitrust litigation over generic price-fixing with direct purchaser plaintiffs.

You may also be interested in...



Sun Ready To Launch AmBisome Rival Soon

Sun launched five generics in the US market during Q3 FY22 and is expecting to launch its generic version of Astellas and Gilead’s AmBisome (amphotericin B liposome injection) shortly. According to the Indian company, new launches and better supply chain management can help drive future growth. 

Sandoz, Apotex And Taro Strike Civil Settlements On Price-Fixing

Three civil settlements worth more than $447m in total have been reached with the US Department of Justice by Sandoz, Apotex and Sun’s Taro to resolve allegations over price-fixing. The deals follow criminal penalties previously paid by the three companies.

Taro Penalties Exceed $400m As It Admits Fixing Prices With Sandoz

In the latest development arising from ongoing generic pricing investigations in the US, Taro has admitted to fixing prices, allocating customers and rigging bids for generic medicines, under a conspiracy with multiple firms, including Sandoz.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB151390

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel